Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 332,150
  • Shares Outstanding, K 25,550
  • Annual Sales, $ 14,800 K
  • Annual Income, $ -90,750 K
  • 60-Month Beta 1.46
  • Price/Sales 24.11
  • Price/Cash Flow N/A
  • Price/Book 1.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.10
  • Number of Estimates 4
  • High Estimate -1.02
  • Low Estimate -1.18
  • Prior Year -1.30
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.75 +3.61%
on 06/24/19
15.02 -12.05%
on 07/01/19
+0.09 (+0.69%)
since 06/21/19
3-Month
12.75 +3.61%
on 06/24/19
17.74 -25.51%
on 05/10/19
-2.34 (-15.05%)
since 04/22/19
52-Week
12.75 +3.61%
on 06/24/19
44.65 -70.41%
on 08/01/18
-28.63 (-68.43%)
since 07/20/18

Most Recent Stories

More News
Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 13.21 (+1.62%)
Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 13.21 (+1.62%)
Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 13.21 (+1.62%)
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.87% and 1.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ASMB : 13.21 (+1.62%)
Assembly Biosciences: 1Q Earnings Snapshot

CARMEL, Ind. (AP) _ Assembly Biosciences Inc. (ASMB) on Thursday reported a loss of $27.1 million in its first quarter.

ASMB : 13.21 (+1.62%)
Assembly Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 13.21 (+1.62%)
Assembly Biosciences Announces Changes to Senior Leadership Team

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 13.21 (+1.62%)
Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 13.21 (+1.62%)
GILD : 64.91 (-0.20%)
Factors of Influence in 2019, Key Indicators and Opportunity within Adobe, CareTrust REIT, Ball, Equinix, Assembly Biosciences, and GTx -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Adobe Systems Incorporated (NASDAQ:ADBE),...

BLL : 71.11 (+0.58%)
ADBE : 308.55 (+0.55%)
ASMB : 13.21 (+1.62%)
CTRE : 23.06 (-0.43%)
EQIX : 506.40 (-0.04%)
GTXI : 1.20 (unch)
Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019

Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations

ASMB : 13.21 (+1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ASMB with:

Business Summary

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for...

See More

Key Turning Points

2nd Resistance Point 13.61
1st Resistance Point 13.41
Last Price 13.21
1st Support Level 13.00
2nd Support Level 12.79

See More

52-Week High 44.65
Fibonacci 61.8% 32.46
Fibonacci 50% 28.70
Fibonacci 38.2% 24.94
Last Price 13.21
52-Week Low 12.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar